Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers
Open accessAbstract
Synapse deterioration underlying severe memory loss in early Alzheimer's disease (AD) is thought to be caused by soluble amyloid beta (Aβ) oligomers. Mechanistically, soluble Aβ oligomers, also referred to as Aβ-derived diffusible ligands (ADDLs), act as highly specific pathogenic ligands, binding to sites localized at particular synapses. This binding triggers oxidative stress, loss of synaptic spines, and ectopic redistribution of receptors critical to plasticity and memory. We report here the existence of a protective mechanism that naturally shields synapses against ADDL-induced deterioration. Synapse pathology was investigated in mature cultures of hippocampal neurons. Before spine loss, ADDLs caused major downregulation of plasma membrane insulin receptors (IRs), via a mechanism sensitive to calcium calmodulin-dependent kinase II (CaMKII) and casein kinase II (CK2) inhibition. Most significantly, this loss of surface IRs, and ADDL-induced oxidative stress and synaptic spine deterioration, could be completely prevented by insulin. At submaximal insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes. The mechanism of insulin protection entailed a marked reduction in pathogenic ADDL binding. Surprisingly, insulin failed to block ADDL binding when IR tyrosine kinase activity was inhibited; in fact, a significant increase in binding was caused by IR inhibition. The protective role of insulin thus derives from IR signaling-dependent downregulation of ADDL binding sites rather than ligand competition. The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.
AI snapshot
Written from the paper’s full text.
TL;DR
In mature hippocampal cultures, insulin signaling prevented Aβ oligomer (ADDL) binding, oxidative stress, insulin receptor loss, and spine degeneration, with protection requiring insulin receptor tyrosine kinase activity rather than simple ligand competition. Rosiglitazone potentiated submaximal insulin’s protection, suggesting that enhancing CNS insulin signaling may defend synapses against Alzheimer’s-linked toxins.
Key findings
- ADDLs caused loss of surface insulin receptors (IRs): surface-exposed IR levels decreased by 22% after 30 min and 68% after 3 h of exposure to 100 nM ADDLs.
- The CK2 inhibitor DMAT completely blocked ADDL-induced loss of both IRs and NMDA receptors; the CaMKII inhibitor KN93 afforded partial protection.
- Insulin at 100 nM partially prevented and 1 μM completely blocked ADDL-induced dendritic IR loss; 1 μM insulin caused a major (≈70%) blockade of ADDL binding, and 100 nM insulin + 10 μM rosiglitazone produced IR levels similar to control or 1 μM insulin.
- Insulin prevented ADDL-induced oxidative stress and 24-h spine degeneration; protection required IR activity, because AG1024 (5 μM) abolished insulin’s ability to block ADDL binding and increased binding when added alone or with insulin.
Methods
- Primary mature hippocampal neuronal cultures were used after 21 DIV and treated at 37 °C for 3 h with 100 nM ADDLs or vehicle; insulin (100 nM or 1 μM) or rosiglitazone (10 μM) was added 30 min before ADDLs, and AG1024 (5 μM) was added 30 min before insulin.
- ADDLs were prepared from Aβ1–42; outcomes were assessed by surface biotinylation/Western blot, immunocytochemistry with IRα and NU4 anti-ADDL antibodies, phalloidin labeling of spines, and dihydroethidium (DHE) for reactive oxygen species.
- Immunofluorescence intensities were analyzed with NIH ImageJ.
Limitations
- The paper states that the nature of the ADDL binding sites “has yet to be determined” and that future identification of proteins lost from the membrane in response to insulin could provide insight into them.
- Evident from the text: all experiments were performed in mature hippocampal neuronal cultures; no in vivo or human data are reported in this study.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 1 cited sources checked · 0 supported · 0 flagged
- Findingown data
DMAT, a CK2 inhibitor, completely blocked ADDL-induced loss of both IRs and NMDARs from dendrites of hippocampal neurons.
“we found that DMAT, a CK2 inhibitor, completely blocked ADDL-induced loss of both IRs and NMDARs from the dendrites of hippocampal neurons”
Quote in the paperSubstantial claim - Interpretationown data
ADDLs have a selective impact in accelerating the endocytosis of particular surface proteins, such as IRs.
“These results are consistent with the notion that ADDLs have a selective impact in accelerating the endocytosis of particular surface proteins, such as IRs.”
Quote in the paperSubstantial claim - Interpretationown data
Decreased binding is the result of downregulation of ADDL binding sites through a mechanism requiring IR tyrosine kinase activity.
“Decreased binding is the result of downregulation of ADDL binding sites through a mechanism requiring insulin receptor (IR) tyrosine kinase activity.”
Quote in the paperSubstantial claim - Interpretationown data
The beneficial effect of insulin in AD derives at least in part from an acute decrease in ADDL synaptotoxicity.
“Results here support the hypothesis that the beneficial effect of insulin in AD derives at least in part from an acute decrease in ADDL synaptotoxicity.”
Quote in the paperSubstantial claim - Interpretationown data
The current finding that rosiglitazone potentiates the ability of insulin to protect synapses against ADDLs provides a plausible mechanism of protection.
“A plausible mechanism of protection is provided by the current finding that rosiglitazone potentiates the ability of insulin to protect synapses against ADDLs.”
Quote in the paperSubstantial claim
- Interpretationreasoning
ADDL-induced loss of IRs might represent an important early mechanism underlying memory impairment and other pathological features of AD.
“Thus, ADDL-induced loss of IRs might represent an important early mechanism underlying memory impairment and other pathological features of AD.”
Quote in the paperSubstantial claim - Interpretationreasoning
Dysfunctional CNS insulin signaling would be an AD risk factor.
“Given that insulin protects neurons against AD-causing neurotoxins, it follows that dysfunctional CNS insulin signaling would be an AD risk factor.”
Quote in the paperSubstantial claim - Interpretationown data
Rosiglitazone potentiates insulin protection against ADDL-induced IR loss.
“indicating potentiation of insulin protection by rosiglitazone.”
Quote in the paperSubstantial claim - Interpretationown data
Insulin signaling plays a role in defending CNS neurons against AD.
“Results strongly support the hypothesis that insulin signaling plays a role in defending CNS neurons against AD and provide a disease-specific basis for treatments based on stimulating CNS insulin pathways.”
Quote in the paperSubstantial claim - Interpretationreasoning
Bolstering brain insulin signaling could have significant potential to slow or deter AD pathogenesis.
“The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.”
Quote in the paperSubstantial claim - Interpretationown data
There exists a protective mechanism that naturally shields synapses against ADDL-induced deterioration.
“We report here the existence of a protective mechanism that naturally shields synapses against ADDL-induced deterioration.”
Quote in the paperSubstantial claim - Interpretationown data
Insulin-dependent regulation of ADDL-binding sites.
“This result suggested an insulin-dependent regulation of ADDL-binding sites.”
Quote in the paperSubstantial claim - Interpretationown data
The protective role of insulin derives from IR signaling-dependent downregulation of ADDL binding sites rather than ligand competition.
“The protective role of insulin thus derives from IR signaling-dependent downregulation of ADDL binding sites rather than ligand competition.”
Quote in the paperSubstantial claim - Interpretationown data
CK2 and CaMKII mediate ADDL-induced loss of synaptic receptors germane to plasticity.
“These results indicate that CK2 and CaMKII mediate ADDL-induced loss of synaptic receptors germane to plasticity.”
Quote in the paperSubstantial claim - Interpretationown data
Neuroprotection by insulin requires IR activity.
“Interestingly, neuroprotection by insulin requires IR activity.”
Quote in the paperSubstantial claim - Interpretationreasoning
The ligand-based attack on specific synapses by ADDLs provides a potentially unifying mechanism for AD pathogenesis.
“By explaining why AD targets memory and accounting for major features of neuropathology, the ligand-based attack on specific synapses by ADDLs provides a potentially unifying mechanism for AD pathogenesis.”
Quote in the paperSubstantial claim
- May combine two claims. 7
- Classified as probably not a substantial claim. 1
May combine two claims.
Findingown dataAG1024 caused significant increases in neuronal ADDL binding both when added alone and in the presence of exogenous insulin.
“In fact, AG1024 caused significant increases in neuronal ADDL binding both when AG1024 was added alone and in the presence of exogenous insulin.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Premisenone givenADDLs are soluble neurotoxins putatively responsible for the synaptic deterioration underlying Alzheimer's memory failure.
“We have identified a unique molecular mechanism that protects CNS neurons against ADDLs, soluble neurotoxins putatively responsible for the synaptic deterioration underlying Alzheimer's memory failure.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningPhysiological insulin and pathological ADDLs negatively regulate the abundance of each other's binding sites, creating a competitive balance between synapse survival and degeneration.
“Thus, physiological insulin and pathological ADDLs negatively regulate the abundance of each other's binding sites, creating a competitive balance between synapse survival and degeneration.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe mechanism of protection does not involve simple competition between ADDLs and insulin for a common binding site on the neuronal surface, but rather is a signaling-dependent downregulation of ADDL binding sites.
“Thus the mechanism of protection does not involve simple competition between ADDLs and insulin for a common binding site on the neuronal surface, but rather is a signaling-dependent downregulation of ADDL binding sites.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataInsulin blocks ADDL binding to synapses, thereby preventing the ensuing neurotoxicity.
“Results show that insulin blocks ADDL binding to synapses, thereby preventing the ensuing neurotoxicity.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataLoss of insulin receptors precedes and is not a consequence of overall collapse and retraction of synaptic spines.
“This indicates that loss of insulin receptors precedes and is not a consequence of overall collapse and retraction of synaptic spines.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationAn elevated risk for AD exists in type 2 diabetes patients, who manifest deficient CNS insulin signaling.
“An elevated risk for AD also exists in type 2 diabetes patients, who manifest deficient CNS insulin signaling.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [31] Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4:147–152. doi: 10.2174/156720507780362137. [[DOI](https://doi.org/10.2174/156720507780362137)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/17430239/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr%20Alzheimer%20Res&title=Insulin%20resistance%20and%20Alzheimer's%20disease%20pathogenesis:%20potential%20mechanisms%20and%20implications%20for%20treatment&author=S%20Craft&volume=4&publication_year=2007&pages=147-152&pmid=17430239&do source
Not checked in the free run.
May combine two claims.
Interpretationown dataInsulin signaling downregulates ADDL binding, while ADDLs downregulate IRs.
“Insulin signaling downregulates ADDL binding, while ADDLs downregulate IRs.”
Quote in the paperSubstantial claim
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Insulin receptor internalization occurs by a mechanism mediated by casein kinase 2 and Ca2+/calmodulin-dependent kinase 2, which also are involved in ADDL-induced internalization of NMDA receptors.
“Internalization occurs by a mechanism mediated by casein kinase 2 (CK2) and Ca2+/calmodulin-dependent kinase 2 (CaMK II), which also are involved in ADDL-induced internalization of NMDA receptors (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
Aβ oligomers induce a striking redistribution of insulin receptors, causing their internalization from dendritic membranes and accumulation in the cell body, which renders neurons insulin resistant.
“Aβ oligomers induce a striking redistribution of IRs, causing their internalization from dendritic membranes and accumulation in the cell body. This renders neurons insulin resistant (De Felice et al., 2009; De Felice et al., 2008; Zhao et al., 2008).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
Insulin itself blocks the pathological binding of Aβ oligomers and the resulting redistribution of insulin receptors and synapse loss.
“insulin itself blocks the pathological binding of Aβ oligomers and the resulting redistribution of IRs and synapse loss (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
Clustering of oligomers at synapses shows a cause-and-effect relationship with characteristic Alzheimer neuropathologies: AD-type tau hyperphosphorylation, redistribution of insulin receptors, spine loss and oxidative stress are manifest exclusively in neurons showing synapses targeted by oligomers.
“Clustering of oligomers at synapses, moreover, shows a cause-and-effect relationship with characteristic Alzheimer neuropathologies. AD type tau hyperphosphorylation (De Felice et al., 2008), redistribution of insulin receptors (De Felice et al., 2009; Zhao et al., 2008), spine loss (Lacor et al., 2007) and oxidative stress (De Felice et al., 2007; Decker et al., 2010a) are manifest exclusively in”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
Pharmacological experiments indicate involvement of CaMKII and casein kinase II in the receptor trafficking dysfunction.
“pharmacological experiments indicate involvement of CaMKII and casein kinase II (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
Several neuronal receptors have been proposed as mediating the effect of Aβ on synaptic plasticity and memory, including α-7-nicotinic, glutamatergic, and insulin receptors.
“Several neuronal receptors have been proposed as mediating the effect of Aβ on synaptic plasticity and memory, including the α-7-nicotinic (16), glutamatergic (39–40), and insulin (14) receptors.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [14]
Deteriorations in the clearance and degradation of Aβ as a result of impaired insulin signalling are discussed as a mechanism that increases the risk of AD and may be improved by insulin administration.
“deteriorations in the clearance and degradation of Aβ as a result of impaired insulin signalling are discussed as a mechanism that increases the risk of AD 135 and may be improved by insulin administration.136,137”
From Intranasal insulin (2021) · cites this paper as [136]
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · see citing works
RetractedSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · see citing works
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · see citing works
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · see citing works
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · see citing works
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · see citing works
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1× · see citing works
“We recently reported that ADDLs cause a major loss of IRs from neuronal dendrites (9), in harmony with the impact of ADDLs on other essential plasticity-related neuronal molecules such as N-methylD-aspartate (NMDA) receptors (18, 20).”
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · see citing works
Self-citationGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · see citing works
Self-citationAMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss
Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., & Malinow, R. (2006) · Neuron · doi:10.1016/j.neuron.2006.10.035 · Cited by 1,042 · see citing works
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038 · see citing works
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989 · see citing works
Self-citationSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · see citing works
Self-citationDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · see citing works
Self-citationGeorganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · see citing works
Self-citationIntranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830 · see citing works
Cognition and synaptic plasticity in diabetes mellitus
Gispen, W. H., & Biessels, G. J. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01656-8 · Cited by 772 · see citing works
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · see citing works
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686 · see citing works
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683 · see citing works
Ho, L., Qin, W., Pompl, P., Xiang, Z.-M., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0978fje · Cited by 646 · see citing works
Watson, G. S. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 597 · see citing works
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · see citing works
Brain Insulin Receptors and Spatial Memory
Zhao, W., Chen, H., Xu, H., Moore, E., Meiri, N., Quon, M. J., & Alkon, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34893 · Cited by 535 · see citing works
Self-citationRole of insulin and insulin receptor in learning and memory
Zhao, W., & Alkon, D. L. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00455-5 · Cited by 492 · see citing works
Self-citationAmyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489 · see citing works
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · see citing works
Klein, W. L., Stine, W. B., & Teplow, D. B. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.010 · Cited by 487 · see citing works
Self-citationAlzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432 · see citing works
Self-citationGrünblatt, E., Šalković‐Petrišić, M., Barilar, J. O., Riederer, P. F., & Hoyer, S. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04368.x · Cited by 376 · see citing works
Progressive dendritic changes in aging human cortex
Scheibel, M. E., Lindsay, R. D., Tomiyasu, U., & Scheibel, A. B. (1975) · Experimental Neurology · doi:10.1016/0014-4886(75)90072-2 · Cited by 365 · see citing works
Cao, D., Lu, H., Lewis, T. L., & Li, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703561200 · Cited by 336 · see citing works
Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases
Ferreira, S. T., Vieira, M. N. N., & De Felice, F. G. (2007) · IUBMB Life · doi:10.1080/15216540701283882 · Cited by 335 · see citing works
Self-citationRosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., & Haynatzki, G. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.018 · Cited by 321 · see citing works
Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Townsend, M., Mehta, T., & Selkoe, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610390200 · Cited by 318 · see citing works
Chung, H. J., Huang, Y. H., Lau, L., & Huganir, R. L. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0546-04.2004 · Cited by 315 · see citing works
Monoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · see citing works
Self-citation18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305 · see citing works
Skeberdis, V. A., Lan, J.-Y., Zheng, X., Zukin, R. S., & Bennett, M. V. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051634698 · Cited by 303 · see citing works
Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, J., & Kern, W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301193 · Cited by 302 · see citing works
Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes
Ryan, C. M., Freed, M. I., Rood, J. A., Cobitz, A. R., Waterhouse, B. R., & Strachan, M. W. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1626 · Cited by 289 · see citing works
Roselli, F., Tirard, M., Lu, J., Hutzler, P., Lamberti, P., Livrea, P., Morabito, M. A., & Almeida, O. F. X. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3034-05.2005 · Cited by 276 · see citing works
The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease
Cole, G. M., & Frautschy, S. A. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.08.009 · Cited by 189 · see citing works
Clodfelder‐Miller, B., Zmijewska, A. A., Johnson, G. V. W., & Jope, R. S. (2006) · Diabetes · doi:10.2337/db06-0485 · Cited by 185 · see citing works
Comparison of Hippocampal Dendritic Spines in Culture and in Brain
Boyer, C., Schikorski, T., & Stevens, C. F. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-14-05294.1998 · Cited by 144 · see citing works
cAMP-Dependent Protein Kinase Mediates Activity-Regulated Synaptic Targeting of NMDA Receptors
Crump, F. T., Dillman, K. S., & Craig, A. M. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05079.2001 · Cited by 139 · see citing works
Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Landreth, G. E. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362092 · Cited by 108 · see citing works
Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation
Lee, C.-C., Kuo, Y.-M., Huang, C.-C., & Hsu, K.-S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.06.014 · Cited by 81 · see citing works
Insulin induces a novel form of postsynaptic mossy fiber long-term depression in the hippocampus
Huang, C., You, J.-L., Lee, C.-C., & Hsu, K. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00238-0 · Cited by 39 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · see citing works
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253 · see citing works
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870 · see citing works
Self-citationBomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 830 · see citing works
Self-citationProtein aggregation diseases: pathogenicity and therapeutic perspectives
Aguzzi, A., & O’Connor, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3050 · Cited by 750 · see citing works
Rajmohan, R., & Reddy, P. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160612 · Cited by 695 · see citing works
Insulin Action in Brain Regulates Systemic Metabolism and Brain Function
Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014) · Diabetes · doi:10.2337/db14-0568 · Cited by 688 · see citing works
Chen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 671 · see citing works
“Some studies have proved that insulin treatment prevents the binding of Ab oligomers with IR and synapse loss (De Felice et al., 2009; Gasparini et al., 2001), as well as improves cognitive dysfunction in AD.”
BackgroundFelice, F. G. D., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 647 · see citing works
Self-citationAgrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630 · see citing works
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628 · see citing works
Self-citationBrain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H. T., & Häring, H. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 632 · see citing works
Amyloid oligomers: formation and toxicity of Aβ oligomers
Sakono, M., & Zako, T. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07568.x · Cited by 602 · see citing works
Kapogiannis, D., & Mattson, M. P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70277-5 · Cited by 594 · see citing works
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546 · see citing works
“PPAR activation may also protect rom direct A oligomer toxicity and glucocorticoid toxicity De Felice et al., 2009; Escribano et al., 2009).”
Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease
Tu, S., Okamoto, S., Lipton, S. A., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-48 · Cited by 582 · see citing works
“Extracellular Aβ oligomers or ADDLs bound to synaptic sites can induce removal of surface insulin receptors and contribute to synaptic loss, which can be rescued by insulin treatment [94].”
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes
Liu, Y. M., Liu, F., Grundke, I., Iqbal, K., & Gong, C. (2011) · The Journal of Pathology · doi:10.1002/path.2912 · Cited by 505 · see citing works
Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 499 · see citing works
“Oligomers can also markedly reduce IR levels and activity within dendrites of hippocampal neurons [62], leading to dendritic and synaptic loss [63].”
BackgroundFreiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., Felice, F. G. D., & Benedict, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0076-8 · Cited by 470 · see citing works
Self-citationSynthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911829107 · Cited by 466 · see citing works
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · see citing works
Self-citationLourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny‐Germano, L., Batista, A. F., Sathler, L. B., Brito‐Moreira, J., Amaral, O. B., Silva, C. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.002 · Cited by 415 · see citing works
Self-citationMolecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna‐Reeves, C. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129001 · Cited by 417 · see citing works
Butterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402 · see citing works
“ronal ROS [190].”
Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease
Nguyen, T. T., Ta, Q., Nguyen, T. K. O., Nguyen, T., & Vo, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093165 · Cited by 338 · see citing works
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389 · see citing works
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373 · see citing works
“Calcium-dependent activation of calcium/calmodulin-dependent kinase II (CaMKII) and casein kinase II (CKII) also appears to mediate removal of NMDARs from synapses (De Felice et al., 2009; not represented in the current scheme).”
BackgroundInfluentialSelf-citationHsu, C.-C., Wahlqvist, M. L., Lee, M.-S., & Tsai, H.-N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101524 · Cited by 372 · see citing works
McClean, P. L., & Hölscher, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 359 · see citing works
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · see citing works
Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 354 · see citing works
“[33] De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, et al.”
Self-citationKim, B., & Feldman, E. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.3 · Cited by 357 · see citing works
Silva, N. M. L. E., Gonçalves, R. A., Pascoal, T. A., Lima‐Filho, R. A. S., Resende, E. D. P. F., Vieira, É. L. M., Teixeira, A. L., de Souza, L. C., Peny, J. A., Fortuna, J. T. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01349-z · Cited by 352 · see citing works
Self-citationTramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347 · see citing works
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339 · see citing works
“Aβ monomers and soluble oligomers bind to IRs, can induce IR internalization in neurons and remove IR from dendrites, imitating what is seen in AD brain (De Felice et al., 2009; Moloney et al., 2010; Zhao et al., 2008, 2009).”
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337 · see citing works
“Because AbOs trigger internalization and redistribution of neuronal IRs [49], it is possible that removal of IRs from the cell surface facilitates IRS-1pSer, a view that is consistent with our finding that insulin blocks both neuronal IR downregulation [50] and IRS-1pSer induced byAbOs [41].”
InfluentialSelf-citationCraft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335 · see citing works
“phorylation in preclinical models [4].”
Alzheimer’s disease and insulin resistance: translating basic science into clinical applications
Felice, F. G. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 328 · see citing works
“Indeed, insulin may have important therapeutic implications in early and/or intermediate phases of AD (20, 119), preventing oligomer binding and blocking the pathology of IRs in cultured neurons (15, 16) and in AD brains (46).”
InfluentialSelf-citationAltered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The Hisayama Study
Hokama, M., Oka, S., Leon, J., Ninomiya, T., Honda, H., Sasaki, K., Iwaki, T., Ohara, T., Sasaki, T., LaFerla, F. M., et al. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht101 · Cited by 319 · see citing works
“It has also been shown that insulin prevents the loss of surface insulin receptors, oxidative stress, and synaptic spine loss in cultured mature hippocampal neurons caused by Aβ-derived diffusible ligands (De Felice et al. 2009).”
BackgroundSynaptic changes in Alzheimer’s disease and its models
Pozueta, J., Lefort, R., & Shelanski, M. L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.050 · Cited by 305 · see citing works
Oxidative stress, protein modification and Alzheimer disease
Tramutola, A., Lanzillotta, C., Perluigi, M., & Butterfield, D. A. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.06.005 · Cited by 303 · see citing works
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 310 · see citing works
Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives
Béard, E., Lengacher, S., Dias, S., Magistretti, P. J., & Finsterwald, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.825816 · Cited by 309 · see citing works
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302 · see citing works
The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer’s Disease
Forny‐Germano, L., Felice, F. G. D., & Vieira, M. N. N. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01027 · Cited by 298 · see citing works
Self-citationAberrant insulin signaling in Alzheimer's disease: current knowledge
Bedse, G., Domenico, F. D., Serviddio, G., & Cassano, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00204 · Cited by 294 · see citing works
“IR down-regulation and synaptic loss are markedly decreased by insulin treatment (de Felice et al., 2009).”
BackgroundResultInfluentialNeill, C. O. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.02.025 · Cited by 292 · see citing works
Chen, X., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 291 · see citing works
Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283 · see citing works
Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease
Akhtar, A., & Sah, S. P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104707 · Cited by 286 · see citing works
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 263 · see citing works
“Insulin has been shown to prevent binding of Aβ to synapses, thus minimizing synaptic damage (De Felice et al., 2009).”
BackgroundThe role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 276 · see citing works
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270 · see citing works
“Conversely, treating AD patients and transgenic animals with intranasal insulin lowers the concentration of soluble Aβ and improves memory (De Felice et al., 2009).”
BackgroundRole of the Blood-Brain Barrier in Central Nervous System Insulin Resistance
Rhea, E. M., & Banks, W. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00521 · Cited by 263 · see citing works
“In addition, Aβ oligomers have been shown to lead to the removal of insulin receptors from the membranes of neuronal processes (Zhao et al., 2008; De Felice et al., 2009).”
BackgroundMa, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012845 · Cited by 262 · see citing works
“On one hand, Ab was shown to impair insulin-PI3K-AKT signaling [2,45–47] and insulin treatment was reported to improve cognitive function in patients with early AD [48], while on the other hand, AD transgenic mice with reduced insulin signaling were reported to be protected against cognitive decline [49].”
BackgroundThe brain as an insulin-sensitive metabolic organ
Milstein, J. L., & Ferris, H. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101234 · Cited by 269 · see citing works
Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions
Halter, J. B., Musi, N., McFarland Horne, F., Crandall, J. P., Goldberg, A., Harkless, L., Hazzard, W. R., Huang, E. S., Kirkman, M. S., Plutzky, J., et al. (2014) · Diabetes · doi:10.2337/db14-0020 · Cited by 255 · see citing works
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256 · see citing works
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248 · see citing works
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 282 · see citing works
Amyloid-β as a Modulator of Synaptic Plasticity
Parihar, M. S., & Brewer, G. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101020 · Cited by 249 · see citing works
“of AMPA and NMDA receptors at the neuronal plasma membrane [74,75,218,219].”
Batista, A. F., Forny‐Germano, L., Clarke, J. R., Silva, N. M. L. E., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F. S., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246 · see citing works
Self-citationPrion protein and Aβ‐related synaptic toxicity impairment
Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M., & Aguzzi, A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000082 · Cited by 242 · see citing works
“Several membrane proteins have been reported to bind soluble Ab oligomers—thereby candidat- ing as potential transducers of toxicity (Deane et al, 2004; De Felice et al, 2009; Shankar et al, 2007; Snyder et al, 2005; Yan et al, 1996).”
Vandal, M., White, P. J., Tremblay, C., St‐Amour, I., Chevrier, G., Émond, V., Lefrançois, D., Virgili, J., Planel, E., Giguère, Y., et al. (2014) · Diabetes · doi:10.2337/db14-0375 · Cited by 232 · see citing works
McNay, E. C., & Recknagel, A. K. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.005 · Cited by 229 · see citing works
“…Ab (Gasparini, Netzer, Greengard, & Xu, 2002; Gasparini et al., 2001; Wei Qiao & Marshal, 2006) and may directly prevent pathogenic Ab binding (De Felice et al., 2009) as well as being able to reverse cognitive deficits and reduce amyloid load in AD patients (Reger et al., 2006b; Reger, Watson,…”
Insulin, cognition, and dementia
Cholerton, B., Baker, L. D., & Craft, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.008 · Cited by 229 · see citing works
“This process was also prevented by pretreatment with insulin (De Felice et al., 2009).”
BackgroundInsulin Resistance in Alzheimer's Disease
Ferreira, L. S. S., Fernandes, C., Vieira, M. N. N., & Felice, F. G. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00830 · Cited by 229 · see citing works
“We identified that insulin prevents Aβ oligomers-induced synapse loss and surface IR reduction in vitro (De Felice et al., 2009) and also rescued the PKRmediated endoplasmic reticulum stress in AD models (Lourenco et al., 2013).”
BackgroundSelf-citationInsulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P., Bézard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 313 · see citing works
“…maintenance, neuronal outgrowth and survival, learning and memory, as well as weight and sexual maintenance and regulation (Banks et al., 2012; Craft and Watson, 2004; De Felice et al., 2009; Dudek et al., 1997; Niswender and Schwartz, 2003; Ott et al., 2012; Plum et al., 2005; Porte et al., 2005).”
The PI3K/Akt signaling axis in Alzheimer’s disease: a valuable target to stimulate or suppress?
Razani, E., Pourbagheri‐Sigaroodi, A., Safaroghli‐Azar, A., Zoghi, A., Bavarsad, M. S., & Bashash, D. (2021) · Cell Stress and Chaperones · doi:10.1007/s12192-021-01231-3 · Cited by 229 · see citing works
“In consistence with this, De Felice et al. also delineated that Aβ 1 3 oligomer decreased the expression of membrane surface IRs through CK2 and CaMKII-dependent manner (Felice 2009).”
BackgroundInsulin receptor signaling in the development of neuronal structure and function
Chiu, S., & Cline, H. T. (2010) · Neural Development · doi:10.1186/1749-8104-5-7 · Cited by 217 · see citing works
“Furthermore, increasing evidence shows that Aβ binds to the insulin receptor, decreases the relative amount of insulin receptor in the dendritic compartment, and causes neuronal oxidative stress and loss of spines [153,169-171].”
Backgroundde Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214 · see citing works
Self-citationDecker, H., Lo, K. Y., Unger, S. M., Ferreira, S. T., & Silverman, M. A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1074-10.2010 · Cited by 216 · see citing works
“Although the mechanism of action of A Os at the plasma membrane is not known specifically, A Os can modulate NMDA and insulin receptors (De Felice et al., 2007, 2009).”
BackgroundSelf-citationInsulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00118 · Cited by 217 · see citing works
Zilberter, Y., & Zilberter, M. Y. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24064 · Cited by 199 · see citing works
“Insulin also blocks Ab binding to synapses, thereby preventing the ensuing neurotoxicity (De Felice et al., 2009; Xie et al., 2002) and Ab-induced loss of insulin receptors from neuronal dendrites (De Felice et al., 2009).”
BackgroundHong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.027 · Cited by 213 · see citing works
Clarke, J. R., Lyra e Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D., Carvalho, B. M., Frazão, R., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404183 · Cited by 214 · see citing works
“AbOs were found to cause internalization and cellular redistribution of insulin receptors, to block downstream hippocampal insulin signaling (De Felice et al, 2009; Ma et al, 2009; Bomfim et al, 2012) and to cause hippocampal endoplasmic reticulum (ER) stress (Lourenco et al, 2013), establishing…”
BackgroundMethodSelf-citationBharadwaj, P., Wijesekara, N., Liyanapathirana, M., Newsholme, P., Ittner, L. M., Fraser, P. E., & Verdile, G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161192 · Cited by 203 · see citing works
Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
Frozza, R. L., Lourenco, M. V., & Felice, F. G. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00037 · Cited by 202 · see citing works
“In addition, they promote tau hyperphosphorylation (De Felice et al., 2008; Jin et al., 2011), impaired axonal transport (Snyder et al., 2005; Decker et al., 2010b; Miñano-Molina et al., 2011; Bomfim et al., 2012), and drive inhibition of long-term potentiation (LTP) and memory impairment (Rowan et…”
BackgroundSelf-citationTahtouh, T., Elkins, J. M., Filippakopoulos, P., Soundararajan, M., Burgy, G., Durieu, É., Cochet, C., Schmid, R. S., Lo, D. C., Delhommel, F., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301034u · Cited by 203 · see citing works
Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function
Gladding, C. M., & Raymond, L. A. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.05.001 · Cited by 197 · see citing works
Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence?
Stanley, M., Macauley, S. L., & Holtzman, D. M. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160493 · Cited by 199 · see citing works
“In vitro studies show that synthetic AβOs co-cultured with neurons can bind to synapses and reduce dendritic spines, an effect that is rescued when treated with high insulin and IS is activated (De Felice et al., 2009).”
Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.063 · Cited by 195 · see citing works
Roles of AMP-activated Protein Kinase in Alzheimer’s Disease
Cai, Z., Yan, L., Li, K., Quazi, S. H., & Zhao, B. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8173-2 · Cited by 193 · see citing works
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191 · see citing works
Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications
Hamed, S. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1293521 · Cited by 190 · see citing works
“amyloid β-oligomer-binding sites [209] and increased oligomer clearance [210], consequently preventing IR internaliza-”
BackgroundFigueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C., Melo, H. M., Mota-Sales, A. P., Saraiva, L. M., Klein, W. L., Sebollela, A. S., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-13.2013 · Cited by 181 · see citing works
“…neurons Previous studies have shown that A Os induce internalization of GluN1-containing NMDARs in cultured hippocampal neurons (Snyder et al., 2005; Lacor et al., 2007; De Felice et al., 2009; Jurgensen et al., 2011) without affecting total cellular levels of GluN1 (Jurgensen et al., 2011).”
BackgroundMethodResultSelf-citationImpaired insulin signalling and allostatic load in Alzheimer disease
Felice, F. G. D., Gonçalves, R. A., & Ferreira, S. T. (2022) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00558-9 · Cited by 180 · see citing works
Self-citationPereira Diniz, L., Tortelli, V., Matias, I., Morgado, J., Bérgamo Araujo, A. P., Melo, H. M., Seixas da Silva, G. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3351-16.2017 · Cited by 171 · see citing works
“…been implicated in A Os binding to the excitatory synaptic terminal, including the NMDA (De Felice et al., 2007), insulin receptors (Zhao et al., 2008; De Felice et al., 2009), AMPA (Zhao et al., 2010), Wnt receptors (Magdesian et al., 2008), and PrP C (Laurén et al., 2009; Beraldo et al., 2016).”
BackgroundSelf-citationIntranasal Insulin for Alzheimer’s Disease
Hallschmid, M. (2021) · CNS Drugs · doi:10.1007/s40263-020-00781-x · Cited by 182 · see citing works
Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease
Paula‐Lima, A. C., Brito‐Moreira, J., & Ferreira, S. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12304 · Cited by 170 · see citing works
“…dysfunction (Saraiva et al. 2010; Paula-Lima et al. 2011; SanMartin et al. 2012), and disruption of fast axonal transport (Decker et al. 2010b) leading to synaptic dysfunction, synapse elimination and, ultimately, cell death (De Felice et al. 2007, 2009; Zhao et al. 2010; Renner et al. 2010; Fig.”
BackgroundResultSelf-citationMetabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer’s Disease
Sun, Y., Ma, C., Sun, H. J., Wang, H., Wei, P., Zhou, Z., Wang, H., Pi, C., Shi, Y., & He, X. (2020) · Journal of Diabetes Research · doi:10.1155/2020/4981814 · Cited by 172 · see citing works
Barone, E., Domenico, F. D., Perluigi, M., & Butterfield, D. (2021) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 155 · see citing works
Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach
Cholerton, B., Baker, L. D., Montine, T. J., & Craft, S. (2016) · Diabetes Spectrum · doi:10.2337/ds16-0041 · Cited by 171 · see citing works
Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions
Schiöth, H. B., Craft, S., Brooks, S. J., Frey, W. H., & Benedict, C. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8229-6 · Cited by 168 · see citing works
“Since insulin can mitigate the synaptic loss of hippocampal neurons induced by amyloid beta [48] and regulate glycogen synthase kinase-3 beta, thereby inhibiting the phosphorylation of tau protein that forms neurofibrillary tangles which are a further pathological feature of AD [49], impaired CNS signaling of the horm…”
BackgroundDecker, H., Jürgensen, S., Adrover, M. F., Brito‐Moreira, J., Bomfim, T. R., Klein, W. L., Epstein, A. L., Felice, F. G. D., Jerusalinsky, D. A., & Ferreira, S. T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07058.x · Cited by 164 · see citing works
“Of relevance to the current study, we have recently shown that insulin blocks Ab oligomerbinding to synapses (De Felice et al. 2009).”
BackgroundInfluentialSelf-citationInsulin resistance and pathological brain ageing
Cholerton, B., Baker, L. D., & Craft, S. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03464.x · Cited by 160 · see citing works
Intranasal insulin as a therapeutic option in the treatment of cognitive impairments
Benedict, C., Frey, W. H., Schiöth, H. B., Schultes, B., Jan Born, A., & Hallschmid, M. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.08.026 · Cited by 158 · see citing works
“3; (De Felice et al., 2009)].”
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155 · see citing works
“In addition, insulin resistance in AD might also be stimulated by Aβ monomers and soluble oligomers that bind to IRs, induce IR internalization in neurons and remove IR from dendrites [55,58–61], or inactivate IRS1 through the activation of JNK via TNFα [62,63].”
Roles of O-GlcNAc in chronic diseases of aging
Banerjee, P. S., Lagerlöf, O., & Hart, G. W. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.05.005 · Cited by 157 · see citing works
A Pilot Study of Exenatide Actions in Alzheimer’s Disease
Mullins, R. J., Mustapić, M., Chia, C. W., Carlson, O. D., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S. M., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 160 · see citing works
- Authors
- De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L.
- Affiliations
- Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208; and
- Universidade Federal do Rio de Janeiro (BR)
- Instituto de Bioquímica Médica and
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-02-10
- Volume
- 106
- Issue
- 6
- Pages
- 1971-1976
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2634809
- OpenAlex
- W2097335530
- Semantic Scholar
- f83fd1ab92993abebf2d284fe60d8398949b7908
- Cited by
- 657
- References
- 51
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 17 · 2023: 20 · 2022: 30 · 2021: 41 · 2020: 41 · 2019: 42 · 2018: 44 · 2017: 42 · 2016: 44 · 2015: 53 · 2014: 44 · 2013: 57 · 2012: 46
- FWCI
- 31.69
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-05-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for the National Institutes of Health
- Howard Hughes Medical Institute
- Alzheimer's Association
- American Health Assistance Foundation
- National Institute on Aging (R01AG022547, R01-AG22547, R01-AG18877, R01AG018877)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, insulin signaling, insulin receptor, synaptic plasticity, oxidative stress, CaMKII, casein kinase 2, rosiglitazone, insulin receptor tyrosine kinase, hippocampal neurons, memory loss
- MeSH terms
- Rosiglitazone, Alzheimer Disease, Animals, Cattle, Cells, Cultured, Hippocampus, Humans, Insulin, Neurons, Protein Binding, Receptor, Insulin, Synapses, Signal Transduction, Amyloid beta-Peptides, Oxidative Stress, Dimerization, Protective Agents, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
